PD Dr. med. Daniel Kotlarz, PhD
Kinderklinik und Kinderpoliklinik im Dr. von Haunerschen Kinderspital
LMU Klinikum
Lindwurmstr. 4
80337 München
Phone: +49 89 4400 53123
Email: daniel.kotlarz@med.uni-muenchen.de
University training and degree
1999 – 2007 Human Medicine, Hannover Medical School, Hannover, Germany
Advanced academic qualifications
2014 PhD, Molecular and Cellular Biology (excellent), Department of Pediatric Hematology and Oncology, Hannover Biomedical Research School, Hannover, Germany
Supervisor: Prof. Dr. med. Dr. sci. nat. Christoph Klein
2013 Dr. med. (summa cum laude), Human Medicine, Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany
Supervisor: Prof. Dr. med. Helmut Drexler †
Postgraduate professional career
2017 – Group Leader: Immune and genetic signatures of pediatric IBD
Dr. von Hauner Children’s Hospital, University Hospital, LMU Munich, Germany
2016 – Associated Postdoctoral Research Fellow
Department of Gastroenterology, Hepatology, and Nutrition Research,
Boston Children’s Hospital, Harvard Medical School, Boston, USA
2016 Postdoctoral Research Fellowship
Department of Gastroenterology, Hepatology, and Nutrition Research, Boston Children’s Hospital, Boston, USA (Supervisor: Scott Snapper, MD, PhD)
2014 – 2016 Postdoctoral Research Fellowship
Dr. von Hauner Children’s Hospital, University Hospital, LMU Munich, Germany (Supervisor: Prof. Dr. med. Dr. sci. nat. Christoph Klein)
2014 – Resident Physician in Pediatrics
Dr. von Hauner Children’s Hospital, University Hospital, LMU Munich, Germany
2020 Heinz Maier-Leibnitz-Preis, DFG and BMBF
2019 John Harries Prize, European Society of Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN)
2019 Best Paper Prize, German Society of Paediatric Gastroenterology and Nutrition (GPGE)
2018 Rolf Becker-Preis 2018, LMU Munich (best publication 2017/2018)
2018 Best Presentation Award, 34th Annual Meeting of the GPGE
2017 – 2018 Postdoctoral scholarship, Daimler and Benz Foundation
2017 – 2018 Postdoctoral Fellowship, Else Kröner-Fresenius-Stiftung Clinical Research School
2015 Early Investigators’ Exchange Award, International Pediatric Research Foundation
2015 Innovation Prize, German University Hospital Association
2014 Abstract Achievement Award, American Society of Hematology
2014 Dr. Holger Müller Prize 2013, Dr. Holger Müller Stiftung
2014 – 2016 Postdoctoral fellowship, Reinhard-Frank Stiftung
2013 Young Investigator Award, 46th Annual Meeting of the ESPGHAN
2012 John Harries Prize, ESPGHAN
2012 Young Investigator Award, 45th Annual Meeting of the ESPGHAN
2012 Best Presentation Award, 27th Annual Meeting of the GPGE
2011 Dr. Wilhelm Friedrich Fischer Research Prize, Dr. Wilhelm Friedrich Fischer Stiftung
2007 – 2010 Research scholarship, Deutsche José Carreras Leukämie-Stiftung
2007 – 2008 Scholarship, MD/PhD program “Molecular Medicine”, Hannover Medical School
2005 – 2007 Research scholarship, Herbert-Quandt-Stiftung of the VARTA AG
a) Articles published by outlets with scientific quality assurance, book publications and works accepted for publication, but not yet published
1. Kobold S, Steffen J, Grassmann S, Henkel J, Castoldi R, Zeng Y, Schmollinger JC, Schnurr M, Rothenfußer S, Sustmann C, Niederfellner G, Klein C, Bourquin C and Endres S: Selective bispecific T cell recruiting antibody and antitumor activity of adoptive T cell transfer Journal of the National Cancer Institute 2015; 107(1):364.
2. Kobold S, Grassmann S, Chaloupka M, Lampert C, Wenk S, Kraus F, Rapp M, Düwell P, Zeng Y, Schmollinger JC, Schnurr M, Endres S and Rothenfußer S:Impact of a New Fusion Receptor on PD-1-Mediated Immunosuppression in Adoptive T Cell Therapy. Journal of the National Cancer Institute 2015;107 (8)
3. Rapp M, Grassmann S, Chaloupka M, Layritz P, Kruger S, Ormanns S, Jansen KP, Endres S, Anz D and Kobold S: C-C chemokine receptor type 4 transduction of T cells enhances interaction with dendritic cells, tumor infiltration and therapeutic efficacy of adoptive T cell transfer. Oncoimmunology 2016, 5(3)
4. Wiedemann GM, Jacobi SJ, Chaloupka M, Hamm S, Strobl S, Baumgartner R, Rothenfusser S, Duewell P, Endres S and Kobold S: A novel TLR7 agonist reverses NK cell anergy and cures lymphoma-bearing mice. Oncoimmunology 2016, 5(7)
5. Voigt C, May P, Gottschlich A, Markota A, Wenk D, Gerlach I, Voigt S, Stathopoulos GT, Arendt KAM, Heise C, Rataj F, Janssen KP, Königshoff M, Winter H, Himsl I, Thasler WE, Schnurr M, Rothenfußer S, Endres S, Kobold S: Cancer cells induce interleukin-22 production from memory CD4+ T cells via interleukin-1 to promote tumor growth Proceedings of the National Academy of Science USA 2017, 2017 Dec 5;114(49):12994-12999.
6. Ferrari de Andrade L, Tay RE, Pan D, Luoma AM, Ito Y, Badrinath S, Tsoucas D, Franz B, May KF Jr, Harvey CJ, Kobold S, Pyrdol JW, Yoon C, Yuan GC, Hodi FS, Dranoff G, Wucherpfennig KW. Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell-driven tumor immunity. Science 2018, 359(6383):1537-1542.
7. Rataj F, Kraus FBT, Chaloupka M, Grassmann S, Heise C, Duewell P, Endres S and Kobold S: PD1-CD28 fusion protein enables CD4+ T cell help for adoptive T cell therapy in models of pancreatic cancer and non-Hodgkin-lymphoma. Frontiers in immunology 2018, 9:1955.
8. Herrmann M, Krupka C, Deiser K, Lindl B, Rataj F, Mocikat R, Metzeler KH, Spiekermann K, Kobold S, Fenn NC, Subklewe M and Hopfner KP: Bifunctional PD-1 x CD3 x CD33 fusion protein reverses adaptive immune escape in Acute Myeloid Leukemia.
Blood 2018, 132(23):2484-2494.
9. Rataj F, Jacobi S, Stoiber S, Asang F, Ogonek J, Tokarew N, Cadilha B, van Puijenbroek E, Heise C, Düwell P, Endres S, Klein Ch, Kobold S. High affinity CD16-polymorphism and Fc engineered antibodies enable activity of CD16-chimeric antigen receptor-modified T cells for cancer therapy. British Journal of Cancer 2019; 120(1):79-87.
10. Karches CH, Benmebarek MR, Schmidbauer ML, Kurzay M, Klaus R, Geiger M, Rataj F, Cadilha BL, Lesch S, Heise C, Murr R, vom Berg J, Jastroch M, Lamp D, Duewell P, Niederfellner G, Sustmann C, Endres S, Klein C and Kobold S: Bispecific antibodies activate synthetic agonistic receptor T cells for tumor therapy. Clinical Cancer Research 2019; 25:5890-5900.